drugs

Studies show adverse side effects in Schizophrenia drugs

Tuesday, December 28, 2010 by: Amy Chaves, Ph.D.
Tags: schizophrenia drugs, side effects, health news

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
The five biggest lies about Ebola being pushed by government and mass media
White House admits staging fake vaccination operation to gather DNA from the public
Why does the CDC own a patent on Ebola 'invention?'
Ultraviolet light robot kills Ebola in two minutes; why doesn't every hospital have one of these?
EXCLUSIVE: Natural News tests flu vaccine for heavy metals, finds 25,000 times higher mercury level than EPA limit for water
Irrefutable proof we are all being sprayed with poison: 571 tons of toxic lead 'chemtrailed' into America's skies every year
Truvia sweetener a powerful pesticide; scientists shocked as fruit flies die in less than a week from eating GMO-derived erythritol
Russia taking McDonald's to court, threatens countrywide shutdown
Oregon man serving prison sentence for collecting rainwater on his own property
Senator who attacked Doctor Oz over dietary supplements received over $146,000 in campaign contributions from Big Pharma mega-retailer and Monsanto
Global warming data FAKED by government to fit climate change fictions
Healthy 12-year-old girl dies shortly after receiving HPV vaccine
HOAX confirmed: Michelle Obama 'GMOs for children' campaign a parody of modern agricultural politics
Ebola outbreak may already be uncontrollable; Monsanto invests in Ebola treatment drug company as pandemic spreads
Ben & Jerry's switches to non-GMO, Fair Trade ice cream ingredients
W.H.O. contradicts CDC, admits Ebola can spread via coughing, sneezing and by touching contaminated surfaces
Elliot Rodger, like nearly all young killers, was taking psychiatric drugs (Xanax)
BREAKING: CDC whistleblower confesses to MMR vaccine research fraud in historic public statement
Delicious
(NaturalNews) The November 2010 issue of Nature reported that several large pharmaceutical companies, including AstraZeneca and GlaxoSmithKline, have chosen to pull out of the psychiatric pharmacology in the treatment of schizophrenia. The reason is obvious, according to Nature author, Abbott: The first generation of schizophrenia drugs (manufactured in the 1950s) and the second generation (manufactured in the 1990s) have not addressed the adverse side effects of antipsychotic drugs on patients.

The World Health Organization (WHO) recognizes schizophrenia as a mental disorder that interferes with a person's ability to identify what is real. A person affected with this disorder is not able to manage emotions, cognition, as well as communication. Symptoms could appear in early adolescence as "early flickers of paranoia, hypersensitivity, and hallucination" (Dobbs, 2010). According to WHO, schizophrenia is usually characterized by disruptions in the most fundamental human attributes such as perception, language, thought, emotion, and sense of self. In 2001, WHO estimated that schizophrenia affects 7 per thousand of the adult population (the equivalent of 24 million worldwide), mostly between 15 to 35 years old.

The same November 2010 issue of Nature discussed about a US clinical trial involving nearly 1,500 patients in 57 clinical sites, and at a cost of US$43 million. This trial examined an array of second generation antipsychotic drugs to determine if they were better than the first generation antipsychotic drugs. The clinical trial spanned from 2001-2005. When the results of the unblinded trial were released in 2005, the psychiatric community and pharmacological companies were astounded: the findings suggest that the new drugs were barely different from the old ones.

Although both generations of anti-psychotic drugs were reported to control hallucinations and delusions, patients taking the second generation drugs remained confused, withdrawn, and devoid of drive, the same side effects observed in the first generation drugs. The result of this clinical trial, according to psychiatrist Jeffrey Lieberman, is frustrating and humbling for the research community and it had a chilling effect on the pharmaceutical industry (Abbott, 2010).

A systematic review in 2003 by Bagnall, et al., examined the effectiveness, safety, and cost-effectiveness of atypical antipsychotic drugs used to treat schizophrenia. The review consisted of 171 randomized, controlled trials, of which 28 were from drug manufacturers. Although the review showed that atypical drugs (i.e., risperidone, amisulpride, olanzipine, and clozapine) were seen to be more effective in relieving symptoms of schizophrenia than typical ones, it nonetheless found the following common side-effects: agitation, movement disorders, impotence, dry mouth, nausea and vomiting, dizziness, and weight gain.

The same systematic review examined the safety of these drugs and some of the following adverse reactions were found: death, malignant syndrome, seizures, hepatic dysfunction, and cardiac problems.

A systematic review, involving the application of scientific strategies to limit bias, is a synthesis of relevant studies that address specific clinical questions. Reviews of this kind are considered as the best evidence for making clinical decisions.

The findings of the 2001-2005 US clinical trial and the systematic review of Bagnall, et al. point to the ineffectiveness of anti-psychotic drugs in dealing with schizophrenia. Considering that up to 1% of the world's population is estimated to be affected by this disorder, schizophrenia represents a huge market for any pharmaceutical. However, as research have shown, the pharmaceutical industries have done little in 50 years to address the adverse side-effects that patients have experienced from antipsychotic drugs .

References:

Abbott, A. (11 November, 2010). The drug deadlock. Nature, 468, 158-159.

Bagnall, A. M., Jones, L., Ginnelly, L., Lewis, R., Glanville, J., Gibody, S.,...Kleijnen, J. (2003). A systematic review of atypical antipsychotic drugs in schizophenia (Executive Summary). Health Technology Assessment, 7(13). Retrieved from http://www.hta.ac.uk/pdfexecs/summ713.pdf

Dobbs, D. (11 November, 2010). The making of a troubled mind. Nature, 468, 154-156.

WHO. Schizophrenia. Retrieved from http://www.searo.who.int/en/section1174/sect...


About the author

Amy Chaves is a researcher, teacher, counsellor and writer. She has a Ph.D. in Counselling Psychology from the University of Calgary, Alberta, Canada. She is currently writing a book on connectedness and writes blogs in her website, which can be viewed at http://amychaves.blogspot.com/

Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.